Trial to test CAR T-cell therapies as childhood cancer cures
A first-of-its-kind trial has launched to explore whether personalised CAR T-cell immunotherapy could treat childhood cancers.
The clinical trial, taking place in the UK and US, has enrolled a group of 60 children with cancer and offered them access to personalised investigational therapies. Researchers hope these investigational therapies will prove more effective at treating sarcomas and reduce long-term side effects compared to current standards of care.
The MIGHTY study, led by the NexTGen team comprised of international experts brought together by Cancer Grand Challenges, will evaluate whether CAR T-cell immunotherapy could be an effective treatment for children and young people with difficult-to-treat solid tumours.
“Cancers in children and young people are fundamentally different from those in adults,” said Dr Karin Straathof, Associate Professor in Tumour Immuno-Oncology at UCL and Lead Investigator for the MIGHTY trial.
“They are unique in how they develop, how they resist treatment, and where their vulnerabilities lie. So, the treatments should be different too. While current chemotherapy-based treatments work well for some patients, in other patients the tumour does not respond or comes back.
“We urgently need new treatments that kill cancer cells without harming healthy ones — T-cell immunotherapy has the potential to do just that – not only improve survival but also protect their long-term quality of life. We’re looking forward to seeing the results of this important study.”
Trial brings together ‘best scientists’ for ‘cutting-edge innovation’
Unlike blood cancers, which affect the blood, bone marrow or immune system and do not usually form lumps, solid tumours grow in organs or tissues and often form masses.
Over the past 30 years, there has been little improvement in survival rates for children with these tumours. Current treatment options, many of which were designed for adults decades ag, can cause long-term health effects, such as infertility and learning difficulties. For those who see their cancer return, there are few other treatment options available.
MIGHTY will test CAR T-cell therapies specifically designed for children and young people. CAR T-cell therapy is a type of treatment where a patient’s own T cells, a type of immune cell, are reprogrammed in the lab to better recognise and destroy cancer cells.
“We launched Cancer Grand Challenges to find solutions to the toughest challenges in cancer, and we recognised the urgent need to develop more effective treatments for these children,” said Dr David Scott, Director of Cancer Grand Challenges.
“The launch of this clinical trial represents collaboration between the best scientists from around the world, who we have brought together to develop this cutting-edge innovation.
“We’re incredibly proud to fund and support the NexTGen team, alongside The Mark Foundation for Cancer Research, as their work moves from the lab to the clinic, offering renewed hope to patients and their loved ones.”
